Surrogacy Endpoint for PFS in Follicular Lymphoma Identified

Complete response at 30 months (CR30) may be a useful surrogate endpoint for progression-free survival in trials of first-line follicular lymphoma treatments.

Source: CancerNetwork - January 4, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news